Regeneration of trabecular meshwork in primary open angle glaucoma by stem cell therapy

Glaucoma is considered a neurodegenerative disease due to its pathophysiology and is one of the most common causes of vision loss worldwide. The treatment of glaucoma is essentially based on the reduction of IOP, through pharmacological therapies. The iPSCs enabling autologous transplantation and have the advantage of not generating immune-mediated rejection in the host, that iPSC can be induced to differentiate into a cell type that resembles to TM cells, The iPSC-TM. The data demonstrate that intraocular injection of iPSC-TM prevents the IOP elevation, the aqueous humor outflow reduction and results in preservation of Retinal Ganglion Cell (RGC) density in vivo mice models